Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-03-29
2008-12-09
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S190100, C435S007320
Reexamination Certificate
active
07462699
ABSTRACT:
The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
REFERENCES:
patent: 4551435 (1985-11-01), Liberti et al.
patent: 4643718 (1987-02-01), Marten
patent: 6048529 (2000-04-01), Atassi et al.
patent: 6667158 (2003-12-01), Bavari et al.
patent: 6676622 (2004-01-01), Strahilevitz
patent: 2002/0155114 (2002-10-01), Marks et al.
patent: 2002/0197278 (2002-12-01), Allison
patent: 2004/0101534 (2004-05-01), Diamond
patent: 2004/0110284 (2004-06-01), Bavari et al.
patent: 2004/0175385 (2004-09-01), Marks et al.
patent: 2004/0265935 (2004-12-01), Atassi
patent: 2005/0106182 (2005-05-01), Li et al.
patent: 2007/0172497 (2007-07-01), Atassi
patent: 94/21684 (1994-09-01), None
patent: 2005/014798 (2005-02-01), None
patent: 2005/030119 (2005-04-01), None
Kubota et al, App. and Environmental Microbiology, vol. 63(4), pp. 1214-1218, Apr. 1997, Epitope regions in the Heavy chain ofClostridium botulinumType E, neurotoxin recognized by Monoclonal antibodies.
Doellgast, GJ et al, J. Clinical Microbiology, Mar. 1997, vol. 35(3) pp. 578-583 (abstract only).
Naumann, M et al, J. Neurol. Neurosurg. Psychiatry, 1998, vol. 65, pp. 924-927, Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin.
Samuelsson, Gustav, Transfusion Science, vol. 21, 1999, pp. 215-217.
Amersdorfer et al., “Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries,”Vaccine20:1640-1648 (2002).
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,”Infect. Immun.65:3743-3752 (1997).
Aoki, “Pharmacology and immunology of botulinum toxin serotypes,”J. Neurol.248 Suppl. 1:3-10 (2001).
Atassi and Dolimbek, “Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A,”ProteinJ. 23:39-52 (2004).
Atassi and Oshima, “Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins,”Crit. Revs. Immunol.19:219-260 (1999).
Atassi and Smith, “A proposal for the nomenclature of antigenic sites in peptides and proteins,”Immunochemistry15:609-610 (1978).
Kozaki et al., “Development of antitoxin with each of two complementary fragments ofClostridium botulinumtype B derivative toxin,”Infection and Immunity18:761-766 (1977).
Kozaki et al., “Immunological characterization of Papain-induced fragments ofClostridium botulinumtype A neurotoxin and interaction of the fragments with brain synaptosomes,”Infection and Immunity57:2634-2639 (1989).
Kozaki et al., “The use of monoclonal antibodies to analyze the structure ofClostridium botulinumtype E derivative toxin,”Infection and Immunity52:786-791 (1986).
Krieglstein, Kerstin G. et al, Journal of protein Chemistry, vol. 13(1), pp. 49-57, 1994.
Kubota et al., “Epitope regions in the heavy chain ofClostridium botulinumtype E neurotoxin recognized by monoclonal antibodies,”Applied&Environmental Microbiol.63:1214-1218 (1997).
Lacy et al., “Crystal structure of botulinum neurotoxin type A and implications for toxicity,”Nat. Struct. Biol.5:898-902 (1998).
Lacy, D. B. et al, “Sequence homology and structural analysis of the Clostridial neurotoxins”, Journal of Molecular Biology, vol. 291, 1999, pp. 1091-1104.
LaPenotiere et al., “Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen,”Toxicon33:1383-1386 (1995).
Lebeda, Frank J. et al, “Predicting Differential antigen-antibody contact regions based on solvent accessibility”, Journal of Protein Chemistry, vol. 16(6), 1997, pp. 607-618.
Atassi et al., “Cross-reaction of mouse antibodies against Tetanus neurotoxin with Botulinum neurotoxins A and B,”International Conference 2002, Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Hannover, Germany, Jun. 8-12, Abstract R12 (2002).
Atassi et al., “Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor,”Proc. Natl. Acad. Sci. USA88:3613-3617 (1991).
Atassi et al., “Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with anti-toxin antibodies from three host species,”J. Prot. Chem.15:691-700 (1996).
Atassi, “Immune recognition and cross-reactivity of botulinum neurotoxins,” inScientific and Therapeutic Aspects of Botulinum Toxins(edited by Brin et al.), pp. 385-408, Lippincott Williams and Wilkins, Philadelphia, PA (2002).
Bavari et al., “Identifying the principal antigenic determinants of type A botulinum neurotoxin,”Vaccine16:1850-1856 (1998).
Beecher, DJ et al, J. Protein Chemistry, vol. 16(7), pp. 701-712, 1997.
Byrne, MP et al, vol. 82, 2000, “Development of vaccines for prevention of botulism”, pp. 955-966.
Cenci Di Bello et al., “Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes,”Eur. J. Biochem.219:161-169 (1994).
Chen et al., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,”Infect. Immun.65:1626-1630 (1997).
Clayton and Middlebrook, “Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A,”Vaccine18:1855-1862 (2000).
Clayton et al., “Protective vaccination with a recombinant fragment ofClostridium botulinumneurotoxin serotype A expressed from a synthetic gene inEscherichia coli,” Infect. Immun.63:2738-2742 (1995).
Dertzbaugh and West, “Mapping of protective and cross-reactive domains of the type A neurotoxin ofClostridium botulinum,” Vaccine14:1538-1544 (1996).
Dineen et al, Swiss Prot sequence Q8KHn9, Oct. 1, 2002.
Dolimbek and Atassi, “Protection against alpha-bungarotoxin poisoning by immunization with synthetic toxin peptides,”Mol. Immunol.33:681-689 (1996).
Dolimbek et al., “Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response,”Immunological Investigations31:247-262 (2002).
Dolimbek, BZ et al, Molecular Immunology, vol. 44, pp. 1029-1041, 2007.
Dressler et al., “Antibody-induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses?”Eur. Neurol.47:118-121 (2002).
Gibson et al, Swiss Prot Acession No. Q97TT9, Oct. 1, 2001.
Goschel et al., “Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies—therapeutic consequences,”Exp. Neurol.147:96-102 (1997).
Hambleton et al., “A possible common antigen on clostridial toxins detected by monoclonal anti-botulinum neurotoxin antibodies,” 449-450 (1984).
Hanna, Philip, A. MD, Neurology, vol. 50(6), pp. 1624-1629, Jun. 1998.
Jankovic, Botulinum Toxin: Clinical Implication sof Antigenicity and Immunoresistancey, in Brin et al. eds.,Scientific and Therapeutic Aspects of Botulinum Toxin, pp. 409-415, Lippincott Williams & Wilkins, Philadelphia, PA (2002).
Jankovic, Joseph MD et al, Neurology, vol. 45(9), pp. 1743-1746, Sep. 1995.
Kikuyama eta al, Swiss Prot sequence Q9PRU1, May 1, 2000.
Klein, “Complications and adverse reactions with the use of botulinum toxin,”Dis. Mon.48:336-356 (2002).
Middlebrook, “Protection strategies against botulinum toxin,” an Atassi and Bixler (Eds.),Immunology of Poreteins and Peptides VIIIp. 93-98 Plunum Press New York (1995).
Mullaney et al., “Epitope mapping of neutralizing bo
Allergan Inc.
Baylor College of Medicine
German Joel B.
Navarro Mark
Portner Ginny
LandOfFree
BoNT/A peptides and methods of predicting and reducing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with BoNT/A peptides and methods of predicting and reducing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BoNT/A peptides and methods of predicting and reducing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4048335